Please ensure Javascript is enabled for purposes of website accessibility

GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug

By Eric Volkman - Nov 6, 2017 at 10:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

GW Pharma made an important move with its promising epilepsy treatment Epidiolex.

This year has been a real seesaw for shareholders of GW Pharmaceuticals (GWPH). Lately, that seesaw is tipping up slightly, following news that a cannabidiol-based drug candidate the company developed has been formally submitted to the Food and Drug Administration for review.

That's given some hope to a market that had been quite bearish on GW Pharma's prospects. Here's why.

Pot for a purpose

GW Pharma's drug candidate in question is Epidiolex, a treatment that, in the company's words, "is a pharmaceutical formulation of purified cannabidiol (CBD), which is in development for the treatment of several rare childhood-onset epilepsy disorders." Specifically, these afflictions are Dravet and Lennox-Gastaut (LGS) syndromes.

The company said it completed its FDA New Drug Application to market Epidiolex in the U.S. Additionally, Epidiolex has been granted the FDA's rare pediatric-disease and orphan-drug designations, plus the potentially very helpful Fast Track designation.

Marijuana bud with stethoscope and prescription script

Image source: Getty Images.

Cannabidiol is one of a number of cannabinoids (i.e. the chemical compounds found in marijuana), and it seems to possess certain healing properties. The one product GW Pharma has on the market is Sativex, a cannabidiol-based spray used to treat spasticity in multiple sclerosis patients. It's received marketing authorization in 21 countries, although the U.S. is not one of them yet.

GW Pharma knows its way around cannabinoids -- the company says it's been researching potential medical uses for them since its founding in 1998. In the case of Epidiolex, late-stage clinical trials of the drug indicated that it's effective in the treatment of both Dravet syndrome and LGS. That made GW Pharma an investor favorite among the small group of marijuana-associated stocks on the market.

However, the company fell a few rungs on the popularity ladder in late September when a small biotech, Zogenix (ZGNX), announced much better results from a phase 3 trial of its own Dravet syndrome treatment, fenfluramine -- which is not based on cannabidiol.

GW Pharma's stock understandably took a hit, cratering by 11% on the day Zogenix announced its happy news. Zogenix shares, naturally, rose sharply.

Sparking cautious optimism

The recent Epidiolex announcement returned some optimism -- albeit of the cautious variety -- to GW Pharma's stock, even though the FDA submission was entirely expected by the market. Epidiolex may yet reach the market before Zogenix's fenfluramine, which still requires a late-stage trial before its NDA submission.

We should also remember that Epidiolex and fenfluramine were tested in separate clinical trials and did not go head-to-head, so their results are not necessarily comparable. Also, unlike GW Pharma and Epidiolex, Zogenix has not yet conducted trials on fenfluramine's effect on LGS.

Finally, since epilepsy patients often take more than one drug for their condition, there's a good chance that Epidiolex will be prescribed in addition to other treatments -- although there are concerns about its interaction with different drugs.

GW Pharma investors should keep in mind, however, that Epidiolex is still subject to scheduling -- i.e. categorization -- from the Drug Enforcement Agency. This is because marijuana remains a controlled substance at the federal level. As with any government agency, the DEA can take some time to complete a task.

Investors still have good reason to believe in the company's prospects. Epidiolex might not be the only game in town for its purposes, but it should be an important drug on the market, regardless. Still, investors interested in pot-associated stocks should certainly consider less risky alternatives.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH
Zogenix, Inc. Stock Quote
Zogenix, Inc.
ZGNX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.